SLC15A2 and central nervous system cancer: The greatest difference in mRNA expression was found in SLC15A2 with a 2.66-fold higher mRNA expression in WHO grade II (11.01 ± 1.07) compared to WHO grade IV gliomas (9.60 ± 1.17; p < 0.0005).